Forskolin and Cyclic AMP: How It Actually Works

Almost every plant molecule on this site earns a page because someone hopes it treats something. Forskolin is different. It earned its place in science before anyone tried to sell it, and it earned it for a reason that has nothing to do with health claims: forskolin is one of the small handful of chemicals that let biologists reach inside a living cell and turn a specific signal on at will. Freezers in university laboratories on every continent hold a vial of it. It is in the methods sections of tens of thousands of papers. That is a genuine, verifiable achievement, and it is the most interesting true thing about this plant.

This page explains what forskolin does at the level of the enzyme it grabs, because once you understand the mechanism, two things follow automatically. The first is why forskolin is such a beloved laboratory reagent. The second — and this is the part supplement marketing never mentions — is why the very property that makes it a great research tool makes it a poor candidate for a pill. Those are not two separate facts. They are the same fact seen from two directions.

What Cyclic AMP Is, and Why Cells Bother
Adenylyl Cyclase: The Enzyme Forskolin Grabs
Skipping the Receptor: The Whole Trick
Why Forskolin Became the World's Positive Control
1,9-Dideoxyforskolin and the Logic of Controls
Downstream of cAMP: PKA, CREB and Epac
Not All Nine Cyclases Respond the Same Way
One Signal, a Dozen Different Answers
Universality Is the Problem, Not the Selling Point
From a Dish to a Person: The Gap Nobody Closes
Colforsin: What Happens When Chemists Take It Seriously
What All of This Means If You Are Holding a Bottle
Key Research Papers
Connections

What Cyclic AMP Is, and Why Cells Bother

A cell is wrapped in a fatty membrane that most messenger molecules cannot cross. Adrenaline circulating in your blood never gets inside your heart muscle cells. Glucagon never enters a liver cell. Thyroid-stimulating hormone never enters a thyroid cell. Each of them docks at a protein on the outer surface and stops there.

So the cell needs a relay: something made on the inside, in response to that outside docking, that can spread through the interior and change what the cell is doing. That relay molecule is called a second messenger — the hormone outside being the first messenger — and the most important one in animal biology is cyclic AMP, written cAMP, and named in full 3',5'-cyclic adenosine monophosphate.

Cyclic AMP was discovered in the late 1950s by Earl Sutherland and Theodore Rall, working on how adrenaline makes liver cells release glucose. They found a small, previously unknown nucleotide appearing in the cells after hormone exposure, and they realised they had found the missing link between a hormone on the outside and an enzyme switching on inside. Sutherland received the Nobel Prize in Physiology or Medicine in 1971 for the second-messenger concept. It is not a fringe idea or a supplement-industry talking point; it is one of the load-bearing pillars of modern cell biology.

Two features of cAMP matter for everything that follows:

It is made from ATP, the cell's energy currency. One enzyme snips ATP into a ring shape, and cAMP is the result. The raw material is never in short supply, which means the signal can be produced quickly and in quantity.
It is destroyed just as deliberately as it is made. A family of enzymes called phosphodiesterases chews cAMP apart. The level of cAMP in a cell at any instant is a balance between manufacture and destruction — a tap and a drain, both under control. Caffeine and the asthma drug theophylline work partly by blocking the drain. Forskolin works by opening the tap.

Adenylyl Cyclase: The Enzyme Forskolin Grabs

The tap is an enzyme called adenylyl cyclase (older papers and many supplement labels spell it adenylate cyclase; the two words mean the same enzyme). It sits threaded through the cell membrane, with its working parts hanging on the inside face where the ATP is.

Structurally it is a curious thing. The membrane-spanning portion anchors it in place, and the catalytic machinery is built from two similar but not identical halves, conventionally called C1 and C2, which fold against each other. The active site — where ATP is bent into a ring — sits in the seam between them. That is the important detail, because there is a second pocket in that same seam, roughly opposite the active site, and that second pocket is where forskolin binds.

This was not guesswork. In 1997 two independent structural biology teams published crystal structures of the adenylyl cyclase catalytic core — one from the laboratories of Roger Sunahara, Alfred Gilman and Stephen Sprang, and another from James Hurley's group — and forskolin is sitting right there in the structure, wedged into the interface between the two halves. When forskolin occupies that pocket, it acts like a shim: it pulls the two catalytic halves into the tightly closed, productive arrangement they need to be in to turn ATP into cAMP efficiently.

So the description you see on supplement bottles — "activates adenylate cyclase" — is not marketing embellishment. It is accurate, it has a solved three-dimensional structure behind it, and it is the reason the compound matters at all. Evidence tier for this section: established biochemistry, not a health claim. Nothing here says anything about what a capsule does in a person; it says what a molecule does to an enzyme.

Skipping the Receptor: The Whole Trick

Normally, adenylyl cyclase is not switched on directly. It is switched on through a chain of command:

A hormone docks at a receptor on the cell surface — specifically a G-protein-coupled receptor, the largest receptor family in the human body and the target of roughly a third of all prescription drugs.
The receptor changes shape and activates an attached signalling protein called Gs.
Activated Gs detaches, drifts along the inner face of the membrane, and docks onto adenylyl cyclase.
Adenylyl cyclase switches on, and cAMP rises.

Every step in that chain is a control point. The receptor can be blocked by a drug. It can be desensitised — pulled off the surface and internalised — after too much stimulation. It exists on some cell types and not others. The Gs protein can be modified. All of that regulation is the point: it is how a cell decides whether to listen.

Forskolin walks past the entire chain. Being a small, fat-soluble molecule, it slips straight through the membrane and binds the cyclase itself, at step four. It does not need the hormone, the receptor or the G protein. This is why a pharmacologist calls it a receptor-independent activator, and it has an immediate practical consequence: forskolin works in a cell type whose receptors you do not know, have not identified, or have deliberately blocked.

Hold on to that sentence, because it is simultaneously the reason forskolin is scientifically valuable and the reason it is pharmacologically unpromising. A medicine's job is to act on one tissue and leave the rest alone, and every drug that manages that trick does so by exploiting a receptor that only some cells have. Forskolin is defined by not doing that.

Why Forskolin Became the World's Positive Control

Suppose you are studying a cell line and you want to know whether a particular gene switches on when cAMP rises. You need a way to raise cAMP. Your options:

Find the right hormone for that cell. This means knowing which Gs-coupled receptors the cell expresses, sourcing the matching hormone, and hoping the receptors have not been lost during years of culture. Cultured cell lines lose receptors routinely.
Add cAMP directly. It barely crosses the membrane. Chemically modified analogues exist and are used, but they distribute differently, resist breakdown differently, and hit some downstream targets and not others.
Add forskolin. cAMP goes up. In almost any cell. Reliably, within minutes, at a concentration you can look up in a methods section.

The third option is why forskolin is in the freezer. In the language of experimental design it is a positive control: the manipulation you apply to prove your assay is capable of detecting the thing you are looking for. If forskolin does not produce a cAMP response in your system, your system is broken and you have learned that before you waste six months.

Two papers established this role. In 1981 Kenneth Seamon, Wendell Padgett and John Daly, working at the US National Institutes of Health, published Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells in the Proceedings of the National Academy of Sciences of the USA, showing direct activation in both broken membrane preparations and living cells. Seamon and Daly published a companion account in the Journal of Cyclic Nucleotide Research the same year. The compound itself had been isolated from the root a few years earlier by Indian chemists — Bhat, Bajwa, Dornauer and de Souza reported its structure and stereochemistry in Tetrahedron Letters in 1977, under the name coleonol — but it was the NIH work that made it famous.

By 1989 the role was mature enough to be questioned intelligently: Laurenza, Sutkowski and Seamon published Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? in Trends in Pharmacological Sciences — a paper worth naming here because the honest answer is "the latter as well." Forskolin also interferes with glucose transporters and several ion channels at the concentrations people use. Even as a reagent it is not perfectly clean.

1,9-Dideoxyforskolin and the Logic of Controls

Here is a detail that shows how carefully real researchers treat this molecule, and it is quietly devastating to the idea that "contains forskolin" is a meaningful claim.

The coleus root also contains 1,9-dideoxyforskolin. It differs from forskolin by two missing hydroxyl groups — a trivial-looking change on paper. And it does not activate adenylyl cyclase at all. It still crosses membranes, still lodges in the same fatty environments, and still blocks glucose transport and certain ion channels the way forskolin does. What it cannot do is raise cAMP.

That makes it the perfect negative control. A researcher who sees an effect with forskolin and wants to know whether cAMP caused it repeats the experiment with 1,9-dideoxyforskolin. If the effect vanishes, cAMP was responsible. If the effect persists, it was one of forskolin's off-target actions and the cAMP story was a red herring.

Two lessons follow. First, two nearly identical molecules from the same root have completely different pharmacology — so a root extract is a mixture of agents, some active on the target and some not. Second, professional users of forskolin routinely assume their compound is doing several things at once and design experiments to separate them. That is a more sceptical posture than the one taken by the industry selling the same molecule to consumers.

Downstream of cAMP: PKA, CREB and Epac

Raising cAMP is not the end of the story; it is the start of a branching one. Cyclic AMP has several receivers inside the cell.

Protein kinase A

The main one. Protein kinase A, or PKA, normally sits as a four-part complex: two regulatory subunits clamping two catalytic subunits shut. Four cAMP molecules bind the regulatory pair, the clamp opens, and the catalytic subunits are released to go and attach phosphate groups onto other proteins. Phosphorylation is the cell's general-purpose on-off switch, so a single rise in cAMP can flip dozens of switches at once. Which switches depends entirely on what proteins that particular cell contains.

CREB and gene transcription

Some freed PKA travels into the nucleus and phosphorylates a protein called CREB — cAMP response element-binding protein — which then recruits machinery to switch on genes carrying the matching DNA sequence. This is how a signal lasting minutes produces changes lasting hours or days. It is also why forskolin appears constantly in neuroscience and developmental biology: raising cAMP does not just nudge a cell's activity, it can change which genes it is expressing.

Epac, the second receiver

For decades PKA was assumed to be the only target. In 1998 two groups — de Rooij and Bos in the Netherlands publishing in Nature, and Kawasaki and colleagues publishing in Science — independently identified a different class of cAMP receptor, now called Epac (exchange protein directly activated by cAMP), which activates small G proteins of the Rap family and is entirely independent of PKA. So cAMP has at least two downstream arms, and they do not always agree with each other. In some cell types they push in opposite directions.

Cyclic nucleotide-gated channels

A third receiver, mostly relevant in sensory neurons and specialised tissues: ion channels that open directly when cAMP binds them, with no enzyme in between.

Why this matters for a supplement. "Raises cAMP" is not one action. It is the simultaneous engagement of PKA, of gene transcription through CREB, of Epac and Rap signalling, and of certain ion channels — in whichever tissue the molecule happens to reach. Anyone who tells you the outcome is predictably fat loss is skipping every branch point above.

Not All Nine Cyclases Respond the Same Way

There is a further layer that matters for the honest version of this story. Humans do not have one adenylyl cyclase. There are nine membrane-bound isoforms, numbered one to nine, plus a soluble tenth that is a genuinely different enzyme. Different tissues express different combinations: type five and type six dominate in heart muscle, type three is prominent in olfactory tissue, type one and type eight are calcium-sensitive and concentrated in brain.

Forskolin activates most of them — but not equally, and type nine is essentially forskolin-insensitive. Work from Wei-Jen Tang's laboratory established which residues account for that insensitivity by converting the insensitive enzyme into a sensitive one, published in Molecular Pharmacology in 1998. The soluble cyclase does not respond to forskolin either. Comprehensive treatments of the isoform family were published by Hanoune and Defer in the Annual Review of Pharmacology and Toxicology in 2001 and, more recently, in the International Union of Basic and Clinical Pharmacology review of adenylyl cyclase structures and modulators in Pharmacological Reviews in 2017.

The practical upshot is a nuance that cuts both ways. Forskolin is not perfectly universal, which is why researchers who need isoform specificity have moved to newer, more selective tools. But it is universal enough that a systemic dose would engage cyclases in the great majority of your tissues at once.

One Signal, a Dozen Different Answers

This is the section that makes the safety page comprehensible. Raising cAMP does not mean one thing; it means whatever the local machinery is wired to do. Some of the better-characterised examples:

Fat cell. PKA activates hormone-sensitive lipase and perilipin, and stored triglyceride is broken down into fatty acids — lipolysis. This is the pathway adrenaline uses, and it is the one weight-loss marketing is built on.
Heart muscle cell. PKA phosphorylates calcium channels and calcium-handling proteins; contraction becomes stronger and faster. This is how adrenaline speeds your heart.
Vascular smooth muscle cell. The opposite outcome. PKA reduces the muscle's sensitivity to calcium, the vessel wall relaxes, the vessel widens, and blood pressure falls.
Airway smooth muscle cell. Same relaxation, in the bronchi. This is precisely how a salbutamol inhaler works.
Platelet. cAMP is the platelet's master brake — the signal your own vessel lining uses, via prostacyclin, to stop platelets clumping. Raising it makes platelets less sticky.
Stomach parietal cell. Histamine's H2 receptor signals through cAMP to drive the acid pump. Raising cAMP increases acid secretion — the exact opposite of what an H2 blocker does.
Thyroid follicular cell. The TSH receptor works through cAMP. Raising cAMP mimics the pituitary telling the thyroid to work.
Kidney cyst epithelium. In polycystic kidney disease, cAMP drives both fluid secretion into the cyst and proliferation of its lining. Forskolin is used in the laboratory to induce that behaviour.
Ciliary body of the eye. cAMP-linked signalling governs aqueous humour production, which is why beta-blocker eye drops lower eye pressure.
Neuron. Through PKA and CREB, cAMP participates in the gene expression underlying synaptic plasticity.

Read that list again as a list of side effects and you have the entire cautions section of this topic, derived from first principles. Nothing on it is exotic or speculative. It is the same molecular event arriving in nine tissues that want different things.

Universality Is the Problem, Not the Selling Point

Now put the two halves together.

A drug developer's central problem is selectivity: how do I act on the tissue I care about and nowhere else? Solutions include targeting a receptor only some cells express, delivering the drug locally rather than systemically, or exploiting an enzyme unique to a pathogen.

Forskolin is the anti-selective molecule. Its defining property is that it works without needing the cell to have any particular receptor. In a culture dish that is a gift. In a bloodstream it means the compound cannot distinguish your fat cells from your platelets, your parietal cells or your ciliary body.

So the marketing syllogism — forskolin raises cAMP, cAMP triggers lipolysis, therefore forskolin burns fat — is not wrong in its individual steps. It is wrong in what it omits. The full statement would read: forskolin raises cAMP in every tissue it reaches; in fat cells that promotes lipolysis; in blood vessels it lowers blood pressure; in platelets it impairs clotting; in the stomach it increases acid; in cystic kidney epithelium it drives cyst growth. Presented that way, "raises cAMP throughout the body" reads as what it is: a description of an unselective systemic intervention, not a fat-loss mechanism.

There is a second omission, equally important. Lipolysis is not the same as fat loss. Releasing fatty acids from a fat cell puts them into the bloodstream. If they are not then burned for fuel — because you are eating enough that your body has no need for them — they are simply taken back up and re-esterified into storage. This futile cycle is well described in the metabolism literature and it is the reason a long list of "lipolytic" compounds have failed to move the scale. That argument is developed in full on the weight-loss page.

From a Dish to a Person: The Gap Nobody Closes

Suppose, for argument's sake, that you did want to reproduce a laboratory forskolin effect inside a human body. Four obstacles stand in the way, and they are cumulative.

Concentration. Cell-culture experiments typically use forskolin at one to fifty micromolar, applied in solvent directly to cells in a shallow buffer, with nothing between molecule and target. A capsule has to produce a comparable concentration at a tissue several litres of distribution away.
Solubility. Forskolin is a labdane diterpene — greasy, essentially water-insoluble. This is not a minor formulation nuisance; it is the reason the entire clinical development programme had to chemically modify the molecule rather than use it as found.
First-pass metabolism. Anything absorbed from the gut goes to the liver before it reaches general circulation, and lipophilic plant diterpenes are exactly the substrate class liver enzymes are built to dismantle.
Missing data. This is the most striking part. For a compound with tens of thousands of citations, published human pharmacokinetic data are remarkably thin. There is no widely cited, well-replicated public account of the plasma concentration and time course produced by a standard 25 mg oral dose of forskolin in humans. Search for it yourself. That absence is the single most useful fact about the supplement category, and it is never disclosed on a label.

Without that number, nobody — including the manufacturer — can tell you whether a capsule produces a cAMP-relevant concentration anywhere in your body. Evidence tier: the mechanism is established; the human exposure that would let the mechanism operate is undocumented.

Colforsin: What Happens When Chemists Take It Seriously

There is a real-world test of how promising forskolin looked to people with the resources to develop it properly, and the answer is instructive.

Pharmaceutical chemists did not put forskolin in a capsule. They rebuilt it. A water-soluble derivative — colforsin daropate, developed in Japan and also known by its development code — was synthesised specifically to overcome the solubility problem, and it was approved in Japan as an intravenous agent for acute heart failure, given by infusion under continuous monitoring. An inhaled dry-powder preparation, colforsin, was tested in asthma in the early 1990s.

Notice what every one of those routes has in common: none of them is a swallowed capsule. Intravenous infusion, inhalation, eye drops. When people who understood the molecule wanted a therapeutic effect from it, they either changed the molecule, changed the route, or both — because the natural compound taken orally does not reliably deliver.

This is the single strongest argument against the oral supplement, and it comes not from sceptics but from the drug developers themselves. A different route of administration is a different intervention. The existence of an approved intravenous forskolin derivative in one country tells you the pharmacology is real. It tells you nothing whatsoever about a capsule.

What All of This Means If You Are Holding a Bottle

A summary you can act on:

The mechanism on the label is real. Forskolin does directly activate adenylyl cyclase, there is a crystal structure showing how, and it is a globally used research reagent. You have not been lied to about that. Tier: established biochemistry.
Real mechanism is the weakest form of evidence for a health claim. Mechanism tells you an effect is conceivable. Only a trial in people tells you it happens, and at what size. Mechanistic plausibility is where drug development starts, not where it finishes.
Non-selectivity is a liability. The property being marketed as power — works in any cell, no receptor needed — is the property that makes systemic exposure hard to control.
The dose-to-blood-concentration link is missing. No public human pharmacokinetic account means nobody can connect a capsule to a laboratory concentration.
The successful clinical forms were redesigned and given by other routes. That fact is the whole argument, compressed.

If you want to see how each of these plays out, the sibling pages take them in turn: the weight-loss claim and why it fails, the legitimate clinical research strands in glaucoma and asthma, and the safety and interaction profile that follows directly from the tissue list above.

Key Research Papers

Each entry gives the authors, title, journal and year as plain text. Links are PubMed topic searches built from author names and distinctive title words rather than numeric identifiers, so a link can never silently resolve to the wrong paper.

Rall TW, Sutherland EW. Formation of a cyclic adenine ribonucleotide by tissue particles. Journal of Biological Chemistry, 1958. The discovery of cyclic AMP itself. PubMed search
Bhat SV, Bajwa BS, Dornauer H, de Souza NJ, Fehlhaber HW. Structures and stereochemistry of new labdane diterpenoids from Coleus forskohlii Briq. Tetrahedron Letters, 1977. The isolation and structure of the compound, then called coleonol. PubMed search
Seamon KB, Padgett W, Daly JW. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proceedings of the National Academy of Sciences of the USA, 1981. The foundational demonstration of direct, receptor-independent activation. PubMed search
Seamon KB, Daly JW. Forskolin: a unique diterpene activator of cyclic AMP-generating systems. Journal of Cyclic Nucleotide Research, 1981. The companion account from the same laboratory. PubMed search
Laurenza A, Sutkowski EM, Seamon KB. Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? Trends in Pharmacological Sciences, 1989. An early and honest account of forskolin's off-target actions, including glucose transport and ion channels. PubMed search
Tesmer JJ, Sunahara RK, Gilman AG, Sprang SR. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gs-alpha and GTP-gamma-S. Science, 1997. The structural work in which forskolin is resolved in its binding pocket at the C1–C2 interface. PubMed search
Zhang G, Liu Y, Ruoho AE, Hurley JH. Structure of the adenylyl cyclase catalytic core. Nature, 1997. The independently determined catalytic-core structure published the same year. PubMed search
de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature, 1998. The discovery that cAMP has a second receiver independent of protein kinase A. PubMed search
Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, Graybiel AM. A family of cAMP-binding proteins that directly activate Rap1. Science, 1998. The parallel identification of the same protein family. PubMed search
Yan SZ, Huang ZH, Andrews RK, Tang WJ. Conversion of forskolin-insensitive to forskolin-sensitive (mouse-type IX) adenylyl cyclase. Molecular Pharmacology, 1998. Establishes that isoform nine is not activated by forskolin and identifies why. PubMed search
Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms. Annual Review of Pharmacology and Toxicology, 2001. The standard survey of tissue-specific isoform distribution. PubMed search
Insel PA, Ostrom RS. Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. Cellular and Molecular Neurobiology, 2003. A methodological review of exactly how forskolin is used as a reagent. PubMed search
Dessauer CW, Watts VJ, Ostrom RS, Conti M, Dove S, Seifert R. International Union of Basic and Clinical Pharmacology: structures and small molecule modulators of mammalian adenylyl cyclases. Pharmacological Reviews, 2017. The current authoritative treatment of the enzyme family and its pharmacology. PubMed search

Live PubMed Searches

External Resources

PubChem — the US National Library of Medicine chemical database; search "forskolin" for structure, properties and computed solubility.
RCSB Protein Data Bank — the public repository of solved protein structures, including the adenylyl cyclase catalytic core with forskolin bound.
NIH Office of Dietary Supplements — the US government's reference source on dietary supplement regulation and evidence standards.

Connections

All Herbs
Coleus forskohlii (Forskolin) — the main topic page: botany, naming, traditional use, forms, dosage and cautions.
Forskolin for Weight Loss — what happens when the lipolysis mechanism described here is tested in actual people.
Glaucoma, Asthma and Clinical Research — the routes and doses where the cAMP mechanism did produce measurable clinical effects.
Safety and Interactions — the tissue-by-tissue list above, read as a list of risks.
Polycystic Kidney Disease — the disease in which cAMP is the driver, and the clearest contraindication for this supplement.
Heart Failure — where a redesigned, water-soluble forskolin derivative is used intravenously in one country.
Asthma — airway smooth muscle relaxation via cAMP is exactly how beta-2 agonist inhalers work.
Glaucoma — aqueous humour production is under cAMP-linked control, the basis of beta-blocker eye drops.
Hypothyroidism — the TSH receptor signals through adenylyl cyclase, which is why thyroid tissue responds to forskolin in the laboratory.
Blood Pressure Visualization — an interactive look at vascular tone and the systems that regulate it.
Berberine — another plant compound with a real, well-mapped molecular mechanism and a marketing story that runs ahead of it.

Safety note and disclaimer. This page describes molecular pharmacology, not treatment. Nothing here indicates that a coleus or forskolin supplement is effective or safe for any condition. Because forskolin raises cyclic AMP in whatever tissue it reaches, it has predictable effects on blood pressure, platelet function and gastric acid secretion, and it is flagged as inadvisable in polycystic kidney disease and in pregnancy — see the safety page. This site is educational and is not medical advice. Do not start, stop or change any medication or supplement, and do not delay proven treatment for glaucoma, asthma, high blood pressure or heart disease, without speaking to a qualified clinician who knows your history.

Back to Table of Contents